{ "company": "Hologic", "ticker": "HOLX", "period": { "from": "2026-03-12", "to": "2026-04-11", "days": 30 }, "sentiment_breakdown": { "positive": 43, "negative": 30, "neutral": 54 }, "synthesis": { "executive_summary": "Sentiment analysis for Hologic (HOLX) from 2026-03-12 to 2026-04-11. Analyzed 127 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "date": "2026-04-01", "source": "news", "score": 1.0 }, { "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "date": "2026-03-12", "source": "news", "score": 0.859 }, { "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "date": "2026-03-17", "source": "news", "score": 0.7 }, { "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "date": "2026-03-20", "source": "news", "score": 0.681 }, { "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.557 }, { "title": "Hologic Stock at 52-Week High in 2026: Buy or Sell Ahead of $18.3 Billion Blackstone Takeover Closure?", "date": "2026-04-07", "source": "news", "score": 0.542 }, { "title": "Research Alert: CFRA Drops Coverage On Shares Of Hologic, Inc.", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.527 }, { "title": "Peer- and nurse-led outreach, financial incentives, and point-of-care testing to enhance testing and treatment for hepatitis C among people who have used drugs or experienced homelessness: The REACH_U Study.", "date": "2026 Apr 7", "source": "pubmed", "score": 0.527 }, { "title": "Freshpet Stock Climbs 3% as TD Cowen Raises Rating On Strong Sales", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.511 }, { "title": "Casey’s CEO: Being added to S&P 500 ‘reflects the enduring strength of our business’", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.494 } ], "top_negative": [ { "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "date": "2026-04-11", "source": "pubmed", "score": -0.898 }, { "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "date": "2026-04-09", "source": "news", "score": -0.823 }, { "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "date": "2026-03-27", "source": "news", "score": -0.727 }, { "title": "US stock market today: US stocks rise as Dow, S&P 500 and Nasdaq stay in green, while Nvidia and Tesla stocks continue to slip", "date": "2026-04-06", "source": "news", "score": -0.671 }, { "title": "Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 }, { "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "date": "2026-04-11", "source": "pubmed", "score": -0.66 }, { "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Validation of a Low-Volume (100 μL) Plasma Protocol for HIV-1 RNA Quantification Using the Hologic Aptima HIV-1 Quant Dx Assay.", "date": "2026 Apr 3", "source": "pubmed", "score": -0.612 } ], "raw_data": { "total_items": 127, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-07", "url": "https://www.sec.gov/Archives/edgar/data/859737/000119312526144632/0001193125-26-144632-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-06", "url": "https://www.sec.gov/Archives/edgar/data/859737/000114036126013235/0001140361-26-013235-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Bruker (NASDAQ: BRKR) sets 2026 virtual meeting, pay and auditor votes", "url": "https://www.stocktitan.net/sec-filings/BRKR/def-14a-bruker-corp-definitive-proxy-statement-3549714b6d3b.html", "date": "2026-04-10", "summary": "Bruker Corporation announced details for its 2026 Annual Meeting of Stockholders, which will be held virtually on May 21, 2026. Stockholders will vote on the election of three Class II directors, seek advisory approval for 2025 executive compensation, and ratify PricewaterhouseCoopers as the independent auditor for 2026. The proxy statement also highlights the company's pay-for-performance executive compensation philosophy tied to financial and individual objectives, despite a decline in organic", "sentiment_score": 0.21691, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.720424, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Blackstone and TPG Complete Acquisition of Hologic; Names New CEO", "url": "https://medtechintelligence.com/news_article/blackstone-and-tpg-complete-acquisition-of-hologic-names-new-ceo/amp/", "date": "2026-04-10", "summary": "Blackstone and TPG have completed their acquisition of Hologic, valuing the company at up to $79 per share, making Hologic a private entity. José (Joe) E. Almeida has been appointed as the new Chief Executive Officer, succeeding Stephen MacMillan. The acquisition aims to further Hologic's mission in women's health with increased investment in innovation.", "sentiment_score": 0.006431, "sentiment_label": "Neutral", "relevance_score": 0.307522, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) president exits stock in $76 cash-and-CVR merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-648eec461ef2.html", "date": "2026-04-10", "summary": "Hologic Inc.'s President, GYN Surgical, Brandon Schnittker, has exited his equity holdings in the company as part of its merger into a wholly owned subsidiary of Hopper Parent Inc. The merger deal converted each Hologic share into $76.00 in cash plus one contingent value right (CVR) for up to an additional $3.00, resulting in Schnittker no longer beneficially owning any Hologic common stock. The filing details the disposition of various equity awards, including common stock, non-qualified stock ", "sentiment_score": 0.119816, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) CFO has equity awards cashed out in Hopper merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-35a0bd20b3ee.html", "date": "2026-04-10", "summary": "Hologic Inc.'s Chief Financial Officer Karleen Oberton had her equity awards, including non-qualified stock options, performance stock units, and common stock, cashed out in connection with Hologic's merger with Hopper Parent Inc. Each share of Hologic common stock was converted into $76.00 in cash plus one contingent value right (CVR) worth up to an additional $3.00. As a result, Oberton no longer beneficially owns any Hologic common stock, with her equity position replaced by the cash and CVR ", "sentiment_score": 0.120097, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) COO exits equity as merger pays $76 plus CVR per share", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0b8386fcf7c1.html", "date": "2026-04-10", "summary": "Hologic, Inc.'s Chief Operating Officer, Mitchell D. Essex, has disposed of all his equity holdings in the company following its acquisition. Under the merger terms, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right for up to an additional $3.00, resulting in Essex no longer beneficially owning any Hologic common stock. This Form 4 filing details the mechanics of how his stock options, performance stock units, and common shares were tr", "sentiment_score": 0.119548, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) executive equity awards cancelled and cashed out in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-6ab99e468d3b.html", "date": "2026-04-09", "summary": "Hologic executive Jan Verstreken's equity awards were cancelled and converted into cash and contingent value rights following the company's merger with Hopper Parent Inc. Each Hologic common stock share was converted into $76.00 in cash plus a CVR potentially worth up to $3.00. Verstreken no longer beneficially owns Hologic common stock as a result of this transaction, detailed in a recent Form 4 filing.", "sentiment_score": 0.013238, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) counsel’s shares converted to $76 cash plus CVR in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-a1d8c07801ed.html", "date": "2026-04-09", "summary": "Hologic, Inc. completed a merger in which each share of common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share. As a result, General Counsel Anne M. Liddy disposed of outstanding stock options, performance stock units, restricted stock units, and 28,052 shares of common stock, and no longer beneficially owns any Hologic common stock. This transaction signifies the company's transition to a wholly owned s", "sentiment_score": 0.127193, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) SVP stock converted at $76 plus CVR in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0a0053abe209.html", "date": "2026-04-09", "summary": "Diana De Walt, SVP of Human Resources at Hologic (HOLX), disposed of 7,603 shares due to the company's merger with Hopper Parent Inc. Each share was converted into $76.00 in cash plus one contingent value right (CVR) potentially worth up to $3.00. This transaction resulted in De Walt no longer beneficially owning any Hologic common shares.", "sentiment_score": 0.015498, "sentiment_label": "Neutral", "relevance_score": 0.338335, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits equity as merger pays $76 cash plus CVR", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-b4877956c892.html", "date": "2026-04-09", "summary": "Hologic, Inc. director Stacey D. Stewart reported the disposition of 15,049 non-qualified stock options and 8,358 shares of common stock to the company. These transactions were a direct result of a completed merger where each Hologic common share was converted into $76.00 in cash and one contingent value right of up to $3.00. Stewart no longer beneficially owns Hologic common stock, as his equity awards were converted according to the merger agreement.", "sentiment_score": 0.02456, "sentiment_label": "Neutral", "relevance_score": 0.331595, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits position as merger pays $76 plus CVRs", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-7dc0dcc26cc6.html", "date": "2026-04-09", "summary": "Hologic, Inc. director Christiana Stamoulis has disposed of all her equity holdings in the company, including 50,526 shares of common stock and various non-qualified stock options, as part of a merger deal. Under the terms of the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) that could pay up to an additional $3.00 per share. This transaction leaves Ms. Stamoulis with no remaining Hologic equity.", "sentiment_score": 0.021604, "sentiment_label": "Neutral", "relevance_score": 0.346828, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits stake as Hopper merger pays cash and CVRs", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-69fa98cd6058.html", "date": "2026-04-09", "summary": "Hologic director Wayde D. McMillan has reported the disposition of his equity in the company following its merger with Hopper Parent Inc. McMillan surrendered his non-qualified stock options and common stock, with his time-vesting restricted stock units also converted as per the merger agreement. He no longer beneficially owns any Hologic common stock, with each share converting into $76.00 in cash and one contingent value right potentially worth an additional $3.00.", "sentiment_score": 0.343871, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (NASDAQ: HOLX) director equity cashed out in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-c89d3f95c266.html", "date": "2026-04-09", "summary": "Hologic Inc. director Martin D. Madaus has fully divested his equity holdings in the company due to its recent merger. On April 7, 2026, he surrendered all his non-qualified stock options and common shares, both direct and indirect, as part of the merger agreement where Hologic stock was converted to cash and contingent value rights. This resulted in him no longer beneficially owning any Hologic common stock.", "sentiment_score": -0.107734, "sentiment_label": "Neutral", "relevance_score": 0.953206, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Merger leaves Hologic (HOLX) executive without any common shares", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-75e9ade68ac8.html", "date": "2026-04-09", "summary": "Hologic's President of Diagnostic Solutions, Jennifer M. Schneiders, reported the disposition of 41,462 common shares and various non-qualified stock options and performance stock units as a result of the company's merger. Under the October 21, 2025 merger agreement, each Hologic common share was converted into $76.00 in cash plus a contingent value right of up to $3.00, leading to Schneiders no longer beneficially owning any Hologic common stock. All equity awards were cashed out or converted i", "sentiment_score": 0.053603, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.224, "confidence": 0.22 } }, { "source": "alpha_vantage", "title": "Director leaves Hologic (HOLX) after $76 cash plus CVR merger payout", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-ef341d94e8c6.html", "date": "2026-04-09", "summary": "Hologic director Charles J. Dockendorff has disposed of all his company equity following the company's merger into Hopper Parent Inc. In the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00. This transaction leaves Mr. Dockendorff with no direct or indirect beneficial ownership of Hologic common stock, as detailed in a recent Form 4 filing.", "sentiment_score": 0.00928, "sentiment_label": "Neutral", "relevance_score": 0.307916, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Merger cashes out Hologic (HOLX) director Hantson’s stock and options", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-d8cc2c32963e.html", "date": "2026-04-09", "summary": "Hologic director Ludwig Hantson reported the disposition of all his equity awards, including stock options and common shares, in connection with the company's merger. Under the merger agreement, each Hologic common share was converted into $76.00 in cash plus a contingent value right of up to $3.00. This transaction was a mechanical step due to the merger, not an open-market sale, and Hantson no longer beneficially owns any Hologic common stock.", "sentiment_score": 0.012029, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) officer reports equity cash-out and loss of shares after merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0a9211f5e7b9.html", "date": "2026-04-09", "summary": "Hologic Inc.'s Principal Accounting Officer, Benjamin Jordan Cohn, reported the cash-out and cancellation of his equity awards following the company's merger. This involved the disposition of non-qualified stock options and 17,964 shares of common stock, as each share was converted into $76.00 in cash plus one contingent value right potentially worth up to an additional $3.00. As a result, Cohn no longer beneficially owns any Hologic common stock.", "sentiment_score": 0.048155, "sentiment_label": "Neutral", "relevance_score": 0.310364, "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "Casey’s CEO: Being added to S&P 500 ‘reflects the enduring strength of our business’", "url": "https://cspdailynews.com/company-news/caseys-ceo-being-added-sp-500-reflects-enduring-strength-our-business", "date": "2026-04-09", "summary": "Casey's General Stores Inc. has been added to the S&P 500, a significant milestone for the company since becoming publicly traded in 1983. CEO Darren Rebelez stated that this inclusion reflects the enduring strength, strong financial performance, and ratable growth of their business. Casey's, which replaced Hologic Inc. in the index, has shown robust financial performance, including a 49.3% increase in net income for the third quarter and an expected 18% to 20% increase in fiscal 2026 EBITDA.", "sentiment_score": -0.266319, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.854156, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Casey’s CEO: Being added to S&P 500 ‘reflects the enduring strength of our business’", "url": "https://www.cspdailynews.com/company-news/caseys-ceo-being-added-sp-500-reflects-enduring-strength-our-business", "date": "2026-04-09", "summary": "Casey's General Stores Inc. has been added to the S&P 500, a move its CEO, Darren Rebelez, called a \"significant milestone\" reflecting the business's enduring strength, financial performance, and growth. This marks the first time the convenience-store chain has joined the S&P 500 since going public in 1983. The company, which replaced Hologic Inc., saw strong financial results in its latest quarter, with net income up 49.3%.", "sentiment_score": -0.149514, "sentiment_label": "Neutral", "relevance_score": 0.869596, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "ImpediMed Taps Former Hologic Executive for Top Job", "url": "https://www.mpo-mag.com/breaking-news/impedimed-taps-former-hologic-executive-for-top-job/", "date": "2026-04-09", "summary": "ImpediMed has appointed Erik Anderson, former president of Hologic Inc.'s Breast and Skeletal Health Division, as its new managing director and CEO. Anderson's focus will be on accelerating revenue growth, expanding the adoption of ImpediMed's SOZO platform, particularly in the U.S., and steering the company towards sustainable profitability. This leadership change aims to leverage Anderson's extensive commercial experience in the medical technology sector to capitalize on ImpediMed's growing bu", "sentiment_score": 0.027792, "sentiment_label": "Neutral", "relevance_score": 0.314551, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Freshpet Stock Climbs 3% as TD Cowen Raises Rating On Strong Sales", "url": "https://www.tikr.com/blog/freshpet-stock-climbs-3-as-td-cowen-raises-rating-on-strong-sales", "date": "2026-04-09", "summary": "Freshpet (FRPT) stock rose 3% after TD Cowen upgraded the company to Buy, setting an $80 price target, driven by strong fiscal 2025 results where the company surpassed $1 billion in annual revenue and achieved positive free cash flow a year early. Despite a challenging pet food market, Freshpet outgrew the category, maintained market share, and expanded margins, leading analysts to believe the worst is over and the company's growth trajectory is back on track. The upgrade highlights Freshpet's i", "sentiment_score": 0.221519, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.612964, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Ultra Clean Stock: What the Q4 Earnings Call Revealed About the Next Two Years", "url": "https://www.tikr.com/blog/ultra-clean-stock-what-the-q4-earnings-call-revealed-about-the-next-two-years", "date": "2026-04-09", "summary": "Ultra Clean Holdings (UCTT) is positioning itself for significant growth fueled by AI infrastructure expansion, with its stock up 282% from its 52-week low. The company's \"UCT 3.0\" strategy targets a $4 billion annual revenue run rate by capitalizing on AI, advanced memory, and gate-all-around logic transitions. Analysts are unanimously bullish, with a mean price target of $81.25, suggesting substantial upside as the company's financial performance is expected to recover strongly in 2026 and bey", "sentiment_score": 0.034241, "sentiment_label": "Neutral", "relevance_score": 0.537042, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Casey's General Stores, Inc.(NasdaqGS: CASY) added to S&P 500 Equal Weighted", "url": "https://www.marketscreener.com/news/casey-s-general-stores-inc-nasdaqgs-casy-added-to-s-p-500-equal-weighted-ce7e50dbde8cf526", "date": "2026-04-09", "summary": "Casey's General Stores, Inc. (NasdaqGS: CASY) has been added to the S&P 500 Equal Weighted Index, among several other S&P indices. This move signifies increased visibility for the convenience store and pizza chain, which operates approximately 2,900 stores across 17 states. The addition to the S&P 500 follows an earlier announcement that Casey's would replace Hologic Inc. in the S&P 500 prior to market open on April 9.", "sentiment_score": -0.10976, "sentiment_label": "Neutral", "relevance_score": 0.605311, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic Goes Private In $18 Billion Blackstone, TPG Acquisition", "url": "https://www.sahmcapital.com/news/content/hologic-goes-private-in-18-billion-blackstone-tpg-acquisition-2026-04-08", "date": "2026-04-09", "summary": "Hologic Inc. has completed its $18.3 billion acquisition by funds managed by Blackstone Inc. and TPG Inc. Hologic's stock has ceased trading and will be delisted from Nasdaq. Shareholders will receive $76 per share in cash and a non-tradable contingent value right of up to $3 per share, tied to revenue milestones.", "sentiment_score": 0.414081, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "HOLX Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/HOLX/financials", "date": "2026-04-09", "summary": "The article provides a financial overview of Hologic Inc (HOLX), detailing its revenue breakdown, profitability margins, and competitive positioning. Disposables are identified as the largest revenue contributor at 64.3%, while the company maintains strong gross, operating, and net margins. A comparison with competitors ZBH and WST highlights HOLX's efficient financial performance within the Advanced Medical Equipment & Technology industry.", "sentiment_score": 0.416102, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS:HOLX) dropped from S&P 500 Health Care Equipment & Services (Industry Group)", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-500-health-care-equipment-services-industry-group-ce7e50dbdd89f420", "date": "2026-04-09", "summary": "Hologic, Inc. (NasdaqGS:HOLX) has been removed from the S&P 500 Health Care Equipment & Services Industry Group, as well as multiple other S&P indices including the S&P 500, S&P Global 1200, and S&P Healthcare Equipment Select Industry Index. This news was published on April 8, 2026, at 08:28 pm EDT. Hologic specializes in diagnostic products and medical imaging systems primarily for women's health.", "sentiment_score": -0.442246, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS: HOLX) dropped from S&P 500 Equal Weighted", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-500-equal-weighted-ce7e50dbdd89f522", "date": "2026-04-08", "summary": "Hologic, Inc. (NasdaqGS: HOLX) has been removed from the S&P 500 Equal Weighted index, following its delisting from several other S&P and FTSE indices on April 8th and 9th, 2026. The company specializes in women's health products, including diagnostic tools, medical imaging, and surgical systems. This removal follows a series of similar actions across various major indices, indicating a possible re-evaluation of its market position or index criteria.", "sentiment_score": -0.254007, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS: HOLX) dropped from S&P Composite 1500", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-composite-1500-ce7e50dbdd89f425", "date": "2026-04-08", "summary": "Hologic, Inc. (NasdaqGS:HOLX) was removed from the S&P Composite 1500 index. This delisting marks one of several index removals for the company on April 8th, including the S&P 500 and FTSE All-World Index CI. Hologic specializes in diagnostic products, medical imaging, and surgical products focused on women's health.", "sentiment_score": 0.018506, "sentiment_label": "Neutral", "relevance_score": 0.324827, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic hires former Baxter leader José Almeida as CEO", "url": "https://www.medtechdive.com/news/hologic-hires-ex-baxter-leader-jose-almeida-as-ceo/816919/", "date": "2026-04-08", "summary": "Hologic has appointed José Almeida, former CEO of Baxter, as its new CEO, effective immediately. This appointment coincides with the completion of the $18.3 billion go-private deal by Blackstone and TPG for the women's health company. Almeida's new role will involve leading Hologic as it transitions to a privately owned business, following his previous tenure at Baxter where he focused on strategic repositioning and portfolio changes.", "sentiment_score": 0.143269, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "ImpediMed Selects Former Hologic Executive Erik Anderson as Chief Executive Officer", "url": "https://www.citybiz.co/article/829729/impedimed-selects-former-hologic-executive-erik-anderson-as-chief-executive-officer/", "date": "2026-04-08", "summary": "ImpediMed has appointed Erik Anderson, former President of the Breast and Skeletal Health Division at Hologic, Inc., as its new Managing Director and CEO, effective April 7, 2026. Anderson, who joined ImpediMed's Board in February 2026, will focus on accelerating revenue growth, expanding health system adoption, and working towards cash flow break-even, particularly as the company's Breast Cancer Related Lymphedema (BCRL) business gains momentum. He succeeds Dr. Parmjot Bains, who will continue ", "sentiment_score": 0.257333, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.810912, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Xylem Stock Fell 10% in 2026 While Operating Margins Hit a Four-Year High: Does Wall Street’s $157 Target Hold?", "url": "https://www.tikr.com/blog/xylem-stock-fell-10-in-2026-while-operating-margins-hit-a-four-year-high-does-wall-streets-157-target-hold", "date": "2026-04-08", "summary": "Xylem Inc. (XYL) achieved a four-year high in operating margins in 2025, reaching 14.6%, despite its stock falling 10% in 2026. The company reported record revenue of $9.0 billion for 2025, driven by productivity savings and price realization, with management anticipating further margin expansion and restructuring savings in 2026. Wall Street analysts have a mean price target of $157.12, implying a 26.4% upside, while the TIKR model projects a mid-case target of $188.90 by December 2030, indicat", "sentiment_score": 0.182306, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.597087, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Biotechnology Reagents and Kits Market Set to Witness Rapid Growth Through 2033 | Thermo Fisher Scientific, Inc., QIAGEN, New England Biolabs", "url": "https://www.openpr.com/news/4460206/biotechnology-reagents-and-kits-market-set-to-witness-rapid", "date": "2026-04-08", "summary": "The Biotechnology Reagents and Kits Market is projected to grow from USD 828.0 Mn in 2025 to USD 1,774.0 Mn in 2032, exhibiting an 11.5% CAGR. This market, driven by innovation and investment, is undergoing significant segmentation by kit type, technology, tested parameters, purpose, and end-use across various regions. The report provides a deep dive into market structure, competitive landscape, and strategic insights for decision-makers.", "sentiment_score": 0.344539, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.627517, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Goldman Sachs Adjusts Stryker Price Target to $357 From $403, Maintains Neutral Rating", "url": "https://www.marketscreener.com/news/goldman-sachs-adjusts-stryker-price-target-to-357-from-403-maintains-neutral-rating-ce7e50dad181f527", "date": "2026-04-08", "summary": "Goldman Sachs has adjusted its price target for Stryker (SYK) to $357 from $403, while maintaining a Neutral rating on the stock. This update reflects a change in the firm's outlook for the medical equipment company. The article also notes recent price target adjustments from other analysts, including Citigroup and Evercore ISI.", "sentiment_score": -0.238279, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.640234, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) Stock; Trades Flat as CEO Exit and $18.3B Blackstone-TPG Buyout Nears Final Close", "url": "https://www.mexc.com/news/1012592", "date": "2026-04-08", "summary": "Hologic's shares traded mostly flat as its $18.3 billion acquisition by Blackstone and TPG nears completion, with all regulatory approvals cleared. CEO Steve MacMillan is set to step down following the finalization of the deal, expected around April 7, 2026. Shareholders will receive $76 per share in cash, plus a contingent value right for potential additional payments.", "sentiment_score": 0.133896, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS:HOLX) dropped from S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-500-ex-financials-real-estate-utilities-and-transpor-ce7e50dbdd89f521", "date": "2026-04-08", "summary": "Hologic, Inc. (NasdaqGS:HOLX) has been removed from the S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index, as announced by S&P Capital IQ. The company, a leader in women's health diagnostics and medical imaging, also saw its removal from several other S&P indices on the same date. This change reflects adjustments within these specific market indices.", "sentiment_score": -0.266172, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "[POS AM] HOLOGIC INC SEC Filing", "url": "https://www.stocktitan.net/sec-filings/HOLX/pos-am-hologic-inc-sec-filing-79a3bbaac89f.html", "date": "2026-04-08", "summary": "This SEC filing (Form POS AM) from Hologic, Inc. deregisters securities previously offered under two registration statements (No. 033-65019 and No. 333-73596). The deregistration follows the merger of Hologic with Merger Sub Inc., a wholly-owned subsidiary of Hopper Parent Inc. (Blackstone and TPG), on April 7, 2026, which terminated all prior offerings.", "sentiment_score": 0.04842, "sentiment_label": "Neutral", "relevance_score": 0.336664, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess QuidelOrtho (QDEL) After The Recent Share Price Slump?", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-it-time-to-reassess-quidelortho-qdel-after-the-recent-sha", "date": "2026-04-08", "summary": "This article examines QuidelOrtho (QDEL) after a significant share price decline, finding it undervalued according to Discounted Cash Flow (DCF) and Price/Sales (P/S) analyses. The DCF model suggests an intrinsic value of US$80.65 per share, indicating an 80.3% undervaluation compared to its current price of US$15.88. Additionally, its P/S ratio of 0.40x is well below industry averages and its proprietary Fair Ratio, further suggesting undervaluation.", "sentiment_score": 0.100189, "sentiment_label": "Neutral", "relevance_score": 0.639763, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic goes private in $79 per share buyout by Blackstone, TPG", "url": "https://za.investing.com/news/company-news/hologic-goes-private-in-79-per-share-buyout-by-blackstone-tpg-93CH-4200169", "date": "2026-04-08", "summary": "Hologic Inc. has been acquired by funds managed by Blackstone and TPG, transitioning the women's health company to private ownership in a transaction valued at up to $79 per share. Joe Almeida has been appointed as the new CEO, replacing Stephen MacMillan. The deal includes a cash payment of $76 per share and a contingent value right for up to an additional $3 per share based on future revenue goals.", "sentiment_score": -0.194432, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Research Alert: CFRA Drops Coverage On Shares Of Hologic, Inc.", "url": "https://www.moomoo.com/news/post/67991442/research-alert-cfra-drops-coverage-on-shares-of-hologic-inc", "date": "2026-04-08", "summary": "CFRA has discontinued its coverage on shares of Hologic, Inc. (HOLX). Investors are advised that CFRA will no longer provide updates or research reports on the company.", "sentiment_score": -0.282077, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Blackstone and TPG Complete $18.3B Acquisition of Hologic", "url": "https://dallasinnovates.com/blackstone-and-tpg-complete-18-3b-acquisition-of-hologic/", "date": "2026-04-07", "summary": "Investment firms TPG and Blackstone have finalized their acquisition of medical-technology company Hologic Inc. for up to $18.3 billion. Concurrently, José Almeida has been appointed as the new CEO of Hologic, succeeding Stephen MacMillan. The deal includes a cash payment of $76 per share to Hologic stockholders, with potential additional payments up to $3 per share based on future revenue goals.", "sentiment_score": 0.005754, "sentiment_label": "Neutral", "relevance_score": 0.334511, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Blackstone, TPG Complete $17.2B Acquisition of Hologic", "url": "https://nationaltoday.com/us/ma/marlborough/news/2026/04/07/blackstone-tpg-complete-17-2b-acquisition-of-hologic-1/", "date": "2026-04-07", "summary": "Private equity firms Blackstone and TPG Global, along with Abu Dhabi Investment Authority and GIC Private Limited, have completed their $17.2 billion acquisition of medical diagnostics firm Hologic, Inc. This deal, initially announced in October 2025, underscores a growing investor interest in the medical diagnostics industry and the medical technology sector. Hologic will maintain its Marlborough, Massachusetts headquarters and brand, with a focus on expanding its diagnostic testing and women's", "sentiment_score": 0.335168, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Hologic's $18.3B Buyout: Closing the Deal and the Debt Behind It", "url": "https://www.bitget.com/amp/news/detail/12560605345044", "date": "2026-04-07", "summary": "Hologic's $18.3 billion buyout has officially closed, delisting the company from Nasdaq as it transitions to private ownership. Shareholders received $76 in cash per share plus a contingent value right (CVR) of up to $3, tied to future revenue milestones for the Breast Health business. The acquisition is financed by a substantial $12.25 billion debt package, highlighting a highly leveraged deal with significant interest expenses and a strategic focus on post-closing revenue growth in key segment", "sentiment_score": -0.227118, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Former Baxter chief takes helm at Marlborough medical device maker", "url": "https://www.bizjournals.com/boston/news/2026/04/07/hologic-new-ceo-acquisition.html", "date": "2026-04-07", "summary": "José Almeida, former CEO of Baxter International and Covidien, has been named the new chief executive of Hologic Inc., a Marlborough-based medical device maker. This appointment follows the company's buyout by two private equity firms, prompting the resignation of nine board members as Hologic transitioned to private ownership. Despite its focus on women's health, Hologic has not previously had a female chief executive.", "sentiment_score": 0.104248, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Blackstone, TPG Complete $17.2B Acquisition of Hologic", "url": "https://nationaltoday.com/us/ma/marlborough/news/2026/04/07/blackstone-tpg-complete-17-2b-acquisition-of-hologic/", "date": "2026-04-07", "summary": "Blackstone Inc., TPG Global, LLC, along with the Abu Dhabi Investment Authority and GIC Private Limited, completed their $17.2 billion acquisition of medical diagnostics firm Hologic, Inc. The deal, which first received shareholder and regulatory approvals, including from China and the European Union, is expected to expand the healthcare portfolios of Blackstone and TPG and signals continued private equity interest in the medical technology sector. Hologic will maintain its headquarters in Marlb", "sentiment_score": 0.005237, "sentiment_label": "Neutral", "relevance_score": 0.334154, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "[POS AM] HOLOGIC INC SEC Filing", "url": "https://www.stocktitan.net/sec-filings/HOLX/pos-am-hologic-inc-sec-filing-13595fca0f61.html", "date": "2026-04-07", "summary": "Hologic, Inc. (HOLX) has filed a Post-Effective Amendment to its S-3 Registration Statements, indicating the deregistration of its securities following its acquisition. On April 7, 2026, Hologic merged with Hopper Merger Sub Inc., a wholly-owned subsidiary of Hopper Parent Inc., terminating the offering and sale of Hologic's securities under the previous registration statements. The filing confirms the removal of all unsold securities from registration and the termination of the effectiveness of", "sentiment_score": 0.119405, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic goes private in $79 per share buyout by Blackstone, TPG", "url": "https://in.investing.com/news/company-news/hologic-goes-private-in-79-per-share-buyout-by-blackstone-tpg-93CH-5326042", "date": "2026-04-07", "summary": "Hologic Inc. has transitioned to private ownership in a $79 per share buyout by funds managed by Blackstone and TPG, with minority investments from Abu Dhabi Investment Authority and GIC. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders received $76 per share in cash plus a non-tradable contingent value right of up to $3 per share, dependent on future Breast Health business revenue goals.", "sentiment_score": 0.309416, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "The funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC along with Abu Dhabi Investment Authority and GIC Private Limited completed the acquisition of Hologic, Inc..", "url": "https://www.marketscreener.com/news/the-funds-managed-by-blackstone-inc-nyse-bx-tpg-global-llc-along-with-abu-dhabi-investment-auth-ce7e51d3d18efe20", "date": "2026-04-07", "summary": "Funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC, Abu Dhabi Investment Authority, and GIC Private Limited have completed the acquisition of Hologic, Inc. (NasdaqGS:HOLX) for $17.2 billion. Hologic's common stock ceased trading and was delisted from Nasdaq, and José E. Almeida has been appointed as the new CEO.", "sentiment_score": 0.002463, "sentiment_label": "Neutral", "relevance_score": 0.315786, "sentiment": { "label": "neutral", "score": 0.047, "confidence": 0.05 } }, { "source": "alpha_vantage", "title": "Casey’s joining S&P 500 on Thursday", "url": "https://www.cspdailynews.com/company-news/caseys-joining-sp-500-thursday", "date": "2026-04-07", "summary": "Casey’s General Stores Inc. is set to join the S&P 500 on Thursday, replacing Hologic Inc., which is being acquired. Casey’s shares rose after the announcement and the company recently reported a significant increase in net income for its third quarter, up 49.3% to $130.1 million. The convenience store chain is also the third-largest c-store retailer and fifth-largest pizza chain in the U.S., with plans for continued growth.", "sentiment_score": 0.30631, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.948303, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Casey’s joining S&P 500 on Thursday", "url": "https://cspdailynews.com/company-news/caseys-joining-sp-500-thursday", "date": "2026-04-07", "summary": "Convenience store chain Casey's General Stores Inc. will replace Hologic Inc. in the S&P 500 before trading opens on Thursday. This move follows Casey's strong financial performance, with net income up 49.3% in the third quarter and its stock hitting a 52-week high. The changes are part of the index's quarterly rebalance, often triggering stock buying and selling by funds.", "sentiment_score": -0.349208, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.973035, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic goes private in $79 per share buyout by Blackstone, TPG", "url": "https://www.investing.com/news/company-news/hologic-goes-private-in-79-per-share-buyout-by-blackstone-tpg-93CH-4600810", "date": "2026-04-07", "summary": "Hologic Inc. has completed its acquisition by Blackstone and TPG, transitioning the women's health company to private ownership in a deal valued at up to $79 per share. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders will receive $76 per share in cash plus a contingent value right for up to $3 per share based on future revenue goals, and Hologic's common stock has ceased trading on Nasdaq.", "sentiment_score": 0.509095, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Blackstone and TPG Complete Acquisition of Hologic", "url": "https://www.citybiz.co/article/829194/blackstone-and-tpg-complete-acquisition-of-hologic/", "date": "2026-04-07", "summary": "Blackstone and TPG have completed their acquisition of Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, taking the company private in a transaction valued at up to $79 per share. José (Joe) E. Almeida, former Chairman, President, and CEO of Baxter International Inc., has been appointed as the new Chief Executive Officer of Hologic. The acquisition also includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate o", "sentiment_score": 0.037362, "sentiment_label": "Neutral", "relevance_score": 0.309634, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....", "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html", "date": "2026-04-09", "published_at": "2026-04-09T14:12:00Z", "sentiment": { "label": "negative", "score": -0.823, "confidence": 0.82 } }, { "source": "news", "source_name": "Ibtimes.com.au", "title": "Hologic Stock at 52-Week High in 2026: Buy or Sell Ahead of $18.3 Billion Blackstone Takeover Closure?", "description": "Hologic Inc. shares hit a fresh 52-week high of $76.07 Tuesday as the medical technology company's $18.3 billion buyout by private equity giants Blackstone and TPG appeared on track to close as early as April 7, leaving investors with a narrow window to decid…", "url": "https://www.ibtimes.com.au/hologic-stock-52-week-high-2026-buy-sell-ahead-183-billion-blackstone-takeover-closure-1865697", "date": "2026-04-07", "published_at": "2026-04-07T14:45:36Z", "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "The Times of India", "title": "US stock market today: US stocks rise as Dow, S&P 500 and Nasdaq stay in green, while Nvidia and Tesla stocks continue to slip", "description": "US stock market today is moving higher. The Dow is up over 99 points. The S&P 500 has crossed 6,600. The Nasdaq is close to 22,000. Markets are clearly in the green. But not everything is strong. Nvidia and Tesla are still under pressure. That’s catching atte…", "url": "https://economictimes.indiatimes.com/news/international/us/us-stock-market-today-us-stocks-rise-as-dow-sp-500-and-nasdaq-stay-in-green-while-nvidia-and-tesla-stocks-continue-to-slip/articleshow/130064313.cms", "date": "2026-04-06", "published_at": "2026-04-06T15:11:09Z", "sentiment": { "label": "negative", "score": -0.671, "confidence": 0.67 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Hologic CEO Steve MacMillan to retire after go-private deal", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_1646aab4-2597-4d82-a27e-f62d118b8039", "date": "2026-04-06", "published_at": "2026-04-06T10:49:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider", "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....", "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html", "date": "2026-04-03", "published_at": "2026-04-03T09:00:00Z", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "description": "The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266486/28124/en/Mammography-Workstation-Market-to-Grow-by-500-Million-During-2026-2030-Led-by-Siemens-Healthineers-Fujifilm-and-Koninklijke-Philips.html", "date": "2026-04-01", "published_at": "2026-04-01T11:01:00Z", "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "news", "source_name": "Plos.org", "title": "Genotypic distribution and molecular epidemiology of HPV in women in the UAE using PNA-based RT PCR", "description": "Objectives This study aimed to determine the genotypic distribution and molecular epidemiology of HPVs in PAP smear samples of women in the UAE using a peptide nucleic acid (PNA)-based fluorescence melting curve analysis method. Methods A cross-sectional re…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346052", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook", "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html", "date": "2026-03-30", "published_at": "2026-03-30T08:58:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Devices: Markets and Companies Analysis Report 2026 - Eckert & Ziegler BEBIG, Oncura, GE Healthcare Lead the $210 Billion Industry; Expected to Reach $397 Billion by 2030", "description": "Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, and innovations in chemotherapy & diagnostics fuel the market Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, a…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264356/28124/en/Oncology-Devices-Markets-and-Companies-Analysis-Report-2026-Eckert-Ziegler-BEBIG-Oncura-GE-Healthcare-Lead-the-210-Billion-Industry-Expected-to-Reach-397-Billion-by-2030.html", "date": "2026-03-30", "published_at": "2026-03-30T08:31:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Financial Post", "title": "Inside ‘Project Eagle,’ JPMorgan’s High-Wire Act to Fund EA Deal", "description": "The post from @realDonaldTrump landed at precisely 7:23 a.m. Inside JPMorgan Chase & Co., the final piece of Project Eagle was a go.", "url": "https://financialpost.com/pmn/business-pmn/inside-project-eagle-jpmorgans-high-wire-act-to-fund-ea-deal", "date": "2026-03-28", "published_at": "2026-03-28T19:38:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "description": "Key market opportunities include advancements in digital and 3D mammography, integration of AI and CAD systems, expansion of portable units, and increased government support for early breast cancer detection. Growth in Asia-Pacific and rising breast cancer pr…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263847/28124/en/Mammography-Devices-Market-to-Reach-3-81-Billion-by-2030-Driven-by-Technological-Advancements-and-Rising-Breast-Cancer-Awareness.html", "date": "2026-03-27", "published_at": "2026-03-27T14:30:00Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Pehub.com", "title": "Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza", "description": "Blackstone and TPG's $18.3bn take-private of Hologic, which is expected to close soon, is a bellwether.\nThe post Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza appeared first on PE Hub.", "url": "https://www.pehub.com/?p=20000003725583", "date": "2026-03-26", "published_at": "2026-03-26T16:00:53Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "dicom-hl7-mcp added to PyPI", "description": "DICOM/HL7 Developer AI Assistant — MCP server for healthcare integration engineers", "url": "https://pypi.org/project/dicom-hl7-mcp/", "date": "2026-03-25", "published_at": "2026-03-25T17:27:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "New York Post", "title": "Iga Swiatek parts ways with tennis coach after stunning loss: ‘Worst nightmare’", "description": "Polish tennis star Iga Swiatek has parted ways with her coach, Wim Fissette, who joined in her 2024, after a \"nightmare\" second-round loss at the 2026 Miami Open.", "url": "https://nypost.com/2026/03/23/sports/iga-swiatek-parts-ways-with-tennis-coach-after-stunning-loss-worst-nightmare/", "date": "2026-03-23", "published_at": "2026-03-23T20:55:06Z", "sentiment": { "label": "negative", "score": -0.45, "confidence": 0.45 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Biopsy Devices Market Size Projected to Reach USD 5.08 Billion by 2035; Increasing Incidence of Cancer to Drive Market Growth Globally – SNS Insider", "description": "Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global Market Expansion. Rising Demand for Minimally Invasive, Image-Guided Procedures and Expanding Healthcare Infrastructure Accelerate Global M…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259711/0/en/Biopsy-Devices-Market-Size-Projected-to-Reach-USD-5-08-Billion-by-2035-Increasing-Incidence-of-Cancer-to-Drive-Market-Growth-Globally-SNS-Insider.html", "date": "2026-03-20", "published_at": "2026-03-20T12:14:00Z", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More", "description": "Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The \"U.S. Exosomes Market Size, Share & Trends Analysis Report by Product & Service, Application, Workflow, End Use, and Segment Forecasts, 2026-2033\" has been added to ResearchAndMarkets.com's offering.The U.S. exos…", "url": "https://www.globenewswire.com/news-release/2026/03/20/3259642/28124/en/U-S-Exosomes-Market-to-Skyrocket-During-2026-2033-Reaching-716-8-Million-Analysis-of-Lucrative-Business-Opportunities-and-Key-Players-Danaher-Thermo-Fisher-Scientific-Hologic-Fujif.html", "date": "2026-03-20", "published_at": "2026-03-20T10:45:00Z", "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "news", "source_name": "Forbes", "title": "Why Alexandra Eala Could Be Tennis’ Next Global Trailblazer", "description": "This story is about Alexandra Eala, seeded No. 31 at the Miami Open, and her potential to become the next trailblazing superstar in tennis.", "url": "https://www.forbes.com/sites/merlisalawrencecorbett/2026/03/19/why-alexandra-eala-could-be-tennis-next-global-trailblazer/", "date": "2026-03-19", "published_at": "2026-03-19T20:23:40Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Nature.com", "title": "AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial", "description": "The breast cancer screening trial found that using automated artificial intelligence to triage and support decisions in mammography and digital breast tomosynthesis was not noninferior to double reading.", "url": "https://www.nature.com/articles/s41591-026-04277-x", "date": "2026-03-19", "published_at": "2026-03-19T00:00:00Z", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "news", "source_name": "Plos.org", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women", "description": "Introduction Vaginal washing has been associated with adverse reproductive health outcomes including pelvic inflammatory disease, reduced fecundability, and HIV acquisition. This analysis tested the hypothesis that vaginal washing is associated with increased…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344736", "date": "2026-03-18", "published_at": "2026-03-18T14:00:00Z", "sentiment": { "label": "negative", "score": -0.161, "confidence": 0.16 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Is Hologic Stock Outperforming the Dow?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_19e412a8-8d41-4673-889f-d27d85333fe7", "date": "2026-03-18", "published_at": "2026-03-18T13:59:04Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Gallup.com", "title": "Global Women's Health Shows Signs of Progress; Gaps Remain", "description": "The fifth Hologic Global Women's Health Index shows progress in preventive care and safety, but gaps remain.", "url": "https://news.gallup.com/poll/702947/global-women-health-shows-signs-progress-gaps-remain.aspx", "date": "2026-03-17", "published_at": "2026-03-17T04:01:00Z", "sentiment": { "label": "positive", "score": 0.7, "confidence": 0.7 } }, { "source": "news", "source_name": "Cdc.gov", "title": "Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026", "description": "This report describes interim estimates of 2025-26 seasonal flu vaccine effectiveness.", "url": "https://www.cdc.gov/mmwr/volumes/75/wr/mm7509a2.htm", "date": "2026-03-12", "published_at": "2026-03-12T17:23:11Z", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™", "description": "Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Automation, and Early Disease Detection Market Expansion Accelerates as Clinical Laboratories and Healthcare Systems Prioritize Rapid Diagnostics, Autom…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254849/0/en/Global-In-Vitro-Diagnostics-Market-to-Reach-USD-157-63-Billion-by-2030-MarketsandMarkets.html", "date": "2026-03-12", "published_at": "2026-03-12T14:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "COVID-19 Tests Market Report 2025: Segments, Share, Regulatory, Reimbursement, and Forecasts to 2036", "description": "Opportunities in the COVID-19 tests market include developing innovative products, leveraging global and regional trends, understanding competitive dynamics, and accessing country-specific regulatory and reimbursement insights. Companies can capitalize on mar…", "url": "https://www.globenewswire.com/news-release/2026/03/12/3254589/28124/en/COVID-19-Tests-Market-Report-2025-Segments-Share-Regulatory-Reimbursement-and-Forecasts-to-2036.html", "date": "2026-03-12", "published_at": "2026-03-12T12:04:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "Nature.com", "title": "A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions", "description": "Genome-wide analysis coupled with long-read sequencing identifies a repeat expansion in GOLGA8A associated with high risk for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.", "url": "https://www.nature.com/articles/s41588-026-02537-7", "date": "2026-03-12", "published_at": "2026-03-12T00:00:00Z", "sentiment": { "label": "negative", "score": -0.541, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41961087", "title": "Adjusting fracture probability according to duration of diabetes: the Manitoba BMD Registry.", "authors": "Leslie WD et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41961087/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41957676", "title": "Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.", "authors": "Berman BP et al.", "journal": "Genome biology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41957676/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41953225", "title": "Fetoscopic repair of myeloschisis: optimizing the three-layer closure.", "authors": "Weber MD et al.", "journal": "Neurosurgical focus: Video", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41953225/", "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41950750", "title": "A peer-delivered mobile model to enhance access to hepatitis C point-of-care testing and treatment: The Peers on Wheels study.", "authors": "Stowe MJ et al.", "journal": "The International journal on drug policy", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950750/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950749", "title": "Peer- and nurse-led outreach, financial incentives, and point-of-care testing to enhance testing and treatment for hepatitis C among people who have used drugs or experienced homelessness: The REACH_U Study.", "authors": "Marinho I et al.", "journal": "The International journal on drug policy", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950749/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41937539", "title": "It Is All About Energy-the Changing Role of X-ray Photons in Photon-counting Detector Computed Tomography: What the Radiologist Needs to Know About kV and keV.", "authors": "Hoeijmakers EJI et al.", "journal": "Investigative radiology", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41937539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41936820", "title": "Validation of a Low-Volume (100 μL) Plasma Protocol for HIV-1 RNA Quantification Using the Hologic Aptima HIV-1 Quant Dx Assay.", "authors": "Madurai LS et al.", "journal": "The Journal of molecular diagnostics : JMD", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41936820/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41931983", "title": "Can large language models like ChatGPT and Gemini interpret cervical cytology accurately?", "authors": "Geetha SD", "journal": "Annals of diagnostic pathology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41931983/", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41930568", "title": "Prediction of spontaneous onset of labor at term using clinical, ultrasound, and biochemical data: A multicenter prospective observational study (the PREDICT study).", "authors": "Migliorelli F et al.", "journal": "Acta obstetricia et gynecologica Scandinavica", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41930568/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41927463", "title": "Point-of-care testing for chlamydia and gonorrhoea: a narrative review of patient perspectives and implementation into non-traditional settings.", "authors": "Griner SB et al.", "journal": "Sexually transmitted infections", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41927463/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41925307", "title": "Development and evaluation of dried urine strip for genital chlamydia and gonorrhea testing.", "authors": "Gibbons S et al.", "journal": "Journal of clinical microbiology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925307/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41920021", "title": "Longitudinal Deterioration in Nutritional Status Associated With Increased Risk of Sarcopenia in Community-Dwelling Aged Adults: A Prospective Cohort Study.", "authors": "Lim HJ et al.", "journal": "Journal of cachexia, sarcopenia and muscle", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41920021/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41918854", "title": "Treatment Approaches for Refractory Mycoplasma genitalium Infection.", "authors": "Tenney R et al.", "journal": "Open forum infectious diseases", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41918854/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41915825", "title": "The Vaginal Microbiota in Pig-Tailed Macaques and Colonization with Neisseria gonorrhoeae.", "authors": "Srinivasan S et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41915825/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41914308", "title": "Cervical Cancer Elimination in Australia and the Asia Pacific: Progress and Barriers.", "authors": "Yuill S et al.", "journal": "The Medical journal of Australia", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41914308/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41913316", "title": "Psychosocial Burden of Women With Cervical Intraepithelial Neoplasia in Japan: Results of A Web-Based Survey.", "authors": "Sato K et al.", "journal": "The journal of obstetrics and gynaecology research", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41913316/", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41907870", "title": "Prospective Multicenter Evaluation of Patient Satisfaction and Radiologist Image Interpretation Using the Envision™ Mammography Platform.", "authors": "Parghi CR et al.", "journal": "Medical devices (Auckland, N.Z.)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41907870/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41885612", "title": "Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.", "authors": "Kachikis A et al.", "journal": "The Journal of infectious diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41885439", "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "authors": "Khosropour CM et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885439/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41874876", "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "authors": "Jeng A et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874876/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874107", "title": "Estimating the sensitivity of non-treponemal and treponemal antibody tests in primary syphilis.", "authors": "Sweitzer SF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874107/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41861507", "title": "Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.", "authors": "Conway A et al.", "journal": "The International journal on drug policy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861507/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41858246", "title": "Unsatisfactory ThinPrep Pap Tests: An Educational Approach to Quality.", "authors": "Olson K et al.", "journal": "Diagnostic cytopathology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41858246/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41856415", "title": "BlotDx: A deep learning tool for Western blot-based diagnostics.", "authors": "Liu L et al.", "journal": "Journal of virological methods", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41856415/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41852862", "title": "Management and Outcomes of Complications Related to BioZorb Use in Breast-Conserving Surgery: A Retrospective Single-Center Case Series Analysis.", "authors": "Baz C et al.", "journal": "Ochsner journal", "date": "2026 Sprin", "url": "https://pubmed.ncbi.nlm.nih.gov/41852862/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41849329", "title": "Association between vaginal washing and group B Streptococcus colonization from periconception through the first trimester of pregnancy in a cohort of Kenyan women.", "authors": "Jisuvei CS et al.", "journal": "PloS one", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41849329/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41825191", "title": "2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.", "authors": "Irving SA et al.", "journal": "Vaccine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825191/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41820630", "title": "Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.", "authors": "Kanis JA et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820630/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41820501", "title": "Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.", "authors": "Van Keer S et al.", "journal": "Communications medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41820501/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41818161", "title": "Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.", "authors": "Maloney P et al.", "journal": "MMWR. Morbidity and mortality weekly report", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41818161/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806477", "title": "A 3D-printed anthropomorphic breast phantom with realistic anatomy and attenuation properties for spatially resolved dosimetry in mammography.", "authors": "Liu Y et al.", "journal": "Physics in medicine and biology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41806477/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41747748", "title": "Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.", "authors": "Ndung'u T et al.", "journal": "The lancet. HIV", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41747748/", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41719678", "title": "Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States.", "authors": "Mahtani R et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41719678/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41707479", "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "authors": "Shin DS et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41707479/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41689946", "title": "Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.", "authors": "Ryu JM et al.", "journal": "European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41689946/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41679383", "title": "Agreement and systematic difference between bioelectrical impedance analysis and dual-energy X-ray absorptiometry for appendicular lean mass in 1617 community-dwelling older adults: The Bunkyo Health Study.", "authors": "Nakagata T et al.", "journal": "Clinical nutrition ESPEN", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41679383/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41651703", "title": "The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review.", "authors": "Degenhardt L et al.", "journal": "The International journal on drug policy", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41651703/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41651702", "title": "Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.", "authors": "Santo T Jr et al.", "journal": "The International journal on drug policy", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41651702/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41637791", "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "authors": "O'Regan RM et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41637791/", "sentiment": { "label": "negative", "score": -0.898, "confidence": 0.9 } }, { "source": "pubmed", "pmid": "41504632", "title": "DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.", "authors": "Jhaveri K et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41504632/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41489384", "title": "Evaluation of Alinity m STI Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Female Urogenital Specimens.", "authors": "Gentil LG et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41489384/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41427726", "title": "Evaluation of Alinity m Sexually Transmitted Infection Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Male Urine Specimens.", "authors": "Cullum R et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41427726/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41401234", "title": "Diagnostic accuracy and prognostic value of CMR in patients with suspected acute coronary syndrome: a meta-analysis.", "authors": "van Cauteren YJM et al.", "journal": "European heart journal. Cardiovascular Imaging", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41401234/", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41396705", "title": "Dual Treponemal and Non-Treponemal Rapid Test for Syphilis in People Living with HIV: A Diagnostic Accuracy Study.", "authors": "Fuertes-Bucheli JF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41396705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41334895", "title": "Commercial Artificial Intelligence (AI) Tool for Screening Digital Breast Tomosynthesis: Factors Associated With AI-Based Breast Cancer Detection.", "authors": "Bahl M et al.", "journal": "AJR. American journal of roentgenology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41334895/", "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41192692", "title": "Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.", "authors": "Jachs M et al.", "journal": "Journal of hepatology", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41192692/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41109867", "title": "Computed tomography pulmonary angiography in around-the-clock clinical care with individualised scan protocols: a 5-year observational study on incidence and causes of repeat scanning.", "authors": "Nijssen EC et al.", "journal": "European radiology", "date": "2026-04-11", "url": "https://pubmed.ncbi.nlm.nih.gov/41109867/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } } ] } }